CN112888691B - 吡咯并[2,3-d]嘧啶甲苯磺酸盐、其结晶形式以及有关的制备方法和中间体 - Google Patents
吡咯并[2,3-d]嘧啶甲苯磺酸盐、其结晶形式以及有关的制备方法和中间体 Download PDFInfo
- Publication number
- CN112888691B CN112888691B CN201980069164.0A CN201980069164A CN112888691B CN 112888691 B CN112888691 B CN 112888691B CN 201980069164 A CN201980069164 A CN 201980069164A CN 112888691 B CN112888691 B CN 112888691B
- Authority
- CN
- China
- Prior art keywords
- disease
- cancer
- disorder
- crystalline form
- autoimmune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 239000000543 intermediate Substances 0.000 title description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 239000007787 solid Substances 0.000 claims description 56
- 239000000203 mixture Substances 0.000 claims description 50
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 45
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 26
- 238000005481 NMR spectroscopy Methods 0.000 claims description 22
- 208000035475 disorder Diseases 0.000 claims description 22
- 230000001363 autoimmune Effects 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 12
- 201000004384 Alopecia Diseases 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 238000001069 Raman spectroscopy Methods 0.000 claims description 9
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 9
- 231100000360 alopecia Toxicity 0.000 claims description 9
- 210000000056 organ Anatomy 0.000 claims description 9
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 8
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 8
- 206010052779 Transplant rejections Diseases 0.000 claims description 8
- 206010046851 Uveitis Diseases 0.000 claims description 8
- 230000001154 acute effect Effects 0.000 claims description 8
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 8
- 230000001684 chronic effect Effects 0.000 claims description 8
- 206010023332 keratitis Diseases 0.000 claims description 8
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 7
- 206010013774 Dry eye Diseases 0.000 claims description 7
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims description 7
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 208000003251 Pruritus Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 208000024799 Thyroid disease Diseases 0.000 claims description 5
- 206010047642 Vitiligo Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 206010015037 epilepsy Diseases 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 206010025135 lupus erythematosus Diseases 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 238000002689 xenotransplantation Methods 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims description 4
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims description 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 206010003571 Astrocytoma Diseases 0.000 claims description 4
- 208000004300 Atrophic Gastritis Diseases 0.000 claims description 4
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims description 4
- 208000023328 Basedow disease Diseases 0.000 claims description 4
- 208000009137 Behcet syndrome Diseases 0.000 claims description 4
- 208000020925 Bipolar disease Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- 208000014644 Brain disease Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010006895 Cachexia Diseases 0.000 claims description 4
- 208000015943 Coeliac disease Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- 208000032274 Encephalopathy Diseases 0.000 claims description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 4
- 208000036495 Gastritis atrophic Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 4
- 208000003084 Graves Ophthalmopathy Diseases 0.000 claims description 4
- 208000015023 Graves' disease Diseases 0.000 claims description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 4
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 4
- 208000005100 Herpetic Keratitis Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 4
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 claims description 4
- 201000002287 Keratoconus Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 4
- 201000002481 Myositis Diseases 0.000 claims description 4
- 206010029113 Neovascularisation Diseases 0.000 claims description 4
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 4
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 206010034277 Pemphigoid Diseases 0.000 claims description 4
- 241000721454 Pemphigus Species 0.000 claims description 4
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010036774 Proctitis Diseases 0.000 claims description 4
- 208000033464 Reiter syndrome Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 206010039705 Scleritis Diseases 0.000 claims description 4
- 206010040070 Septic Shock Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 4
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 4
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims description 4
- 208000025865 Ulcer Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 claims description 4
- 206010047115 Vasculitis Diseases 0.000 claims description 4
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 claims description 4
- 201000006966 adult T-cell leukemia Diseases 0.000 claims description 4
- 230000007815 allergy Effects 0.000 claims description 4
- 230000033115 angiogenesis Effects 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 4
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 4
- 230000002612 cardiopulmonary effect Effects 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims description 4
- 230000006720 chronic neuroinflammation Effects 0.000 claims description 4
- 201000010002 cicatricial pemphigoid Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 201000001981 dermatomyositis Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 4
- 230000001079 digestive effect Effects 0.000 claims description 4
- 230000004064 dysfunction Effects 0.000 claims description 4
- 206010014599 encephalitis Diseases 0.000 claims description 4
- 201000002491 encephalomyelitis Diseases 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 208000024908 graft versus host disease Diseases 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 201000010884 herpes simplex virus keratitis Diseases 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 201000010666 keratoconjunctivitis Diseases 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 208000002741 leukoplakia Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000024714 major depressive disease Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000006512 mast cell neoplasm Diseases 0.000 claims description 4
- 208000008585 mastocytosis Diseases 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 208000021039 metastatic melanoma Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 206010028417 myasthenia gravis Diseases 0.000 claims description 4
- 201000008383 nephritis Diseases 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 230000000414 obstructive effect Effects 0.000 claims description 4
- 201000005737 orchitis Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 208000015385 phacoanaphylactic uveitis Diseases 0.000 claims description 4
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 4
- 208000002574 reactive arthritis Diseases 0.000 claims description 4
- 208000023504 respiratory system disease Diseases 0.000 claims description 4
- 201000000306 sarcoidosis Diseases 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 230000036303 septic shock Effects 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 208000020431 spinal cord injury Diseases 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 206010043778 thyroiditis Diseases 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 230000009529 traumatic brain injury Effects 0.000 claims description 4
- 231100000397 ulcer Toxicity 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 201000005539 vernal conjunctivitis Diseases 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 3
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 3
- 201000006474 Brain Ischemia Diseases 0.000 claims description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 3
- 206010060742 Endocrine ophthalmopathy Diseases 0.000 claims description 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 3
- 206010022941 Iridocyclitis Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 201000004612 anterior uveitis Diseases 0.000 claims description 3
- 206010008118 cerebral infarction Diseases 0.000 claims description 3
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims description 3
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims description 3
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims description 3
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 230000002107 myocardial effect Effects 0.000 claims description 2
- 206010054107 Nodule Diseases 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 208000037902 enteropathy Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- -1 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)propyl Chemical group 0.000 abstract description 10
- 150000003839 salts Chemical class 0.000 abstract description 9
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 abstract description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 51
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- 238000000034 method Methods 0.000 description 31
- 239000000243 solution Substances 0.000 description 31
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical class C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 239000000843 powder Substances 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 201000010099 disease Diseases 0.000 description 22
- 150000001875 compounds Chemical class 0.000 description 20
- 239000002904 solvent Substances 0.000 description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 239000000523 sample Substances 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 239000002002 slurry Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 238000001228 spectrum Methods 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 8
- 238000001237 Raman spectrum Methods 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 7
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 7
- 238000004922 13C solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 235000021317 phosphate Nutrition 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 208000030533 eye disease Diseases 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 238000001144 powder X-ray diffraction data Methods 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 3
- XZJMDCIIEROFRY-NWDGAFQWSA-N CCCN(C1)[C@@H](C)CC[C@H]1NC1=NC=NC2=C1C=CN2 Chemical compound CCCN(C1)[C@@H](C)CC[C@H]1NC1=NC=NC2=C1C=CN2 XZJMDCIIEROFRY-NWDGAFQWSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 238000005079 FT-Raman Methods 0.000 description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 239000005909 Kieselgur Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 201000006292 polyarteritis nodosa Diseases 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- CBRJPFGIXUFMTM-WDEREUQCSA-N 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one Chemical compound N1=CN=C(C2=C1NC=C2)N[C@@H]2CC[C@@H](N(C2)C(C=C)=O)C CBRJPFGIXUFMTM-WDEREUQCSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- 102000015617 Janus Kinases Human genes 0.000 description 2
- 108010024121 Janus Kinases Proteins 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- 208000002231 Muscle Neoplasms Diseases 0.000 description 2
- XRVLBRUVRKUWIN-NWDGAFQWSA-N N-[(3R,6S)-6-methyl-1-prop-2-enylpiperidin-3-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C[C@@H]1N(C[C@@H](CC1)NC=1C2=C(N=CN=1)NC=C2)CC=C XRVLBRUVRKUWIN-NWDGAFQWSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 229940011051 isopropyl acetate Drugs 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 201000002077 muscle cancer Diseases 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001823 pruritic effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 description 1
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002027 Amyotrophy Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- YOZLVAFWYLSRRN-VZXYPILPSA-N C[C@H]1CC[C@H](CN1C(=O)C=C)NC2=NC=NC3=C2C=CN3.CC1=CC=C(C=C1)S(=O)(=O)O Chemical compound C[C@H]1CC[C@H](CN1C(=O)C=C)NC2=NC=NC3=C2C=CN3.CC1=CC=C(C=C1)S(=O)(=O)O YOZLVAFWYLSRRN-VZXYPILPSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010011715 Cyclitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- 208000022461 Glomerular disease Diseases 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 238000001530 Raman microscopy Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- MWKAMUJIXBCKIH-WCQYABFASA-N benzyl (2s,5r)-5-amino-2-methylpiperidine-1-carboxylate Chemical compound C[C@H]1CC[C@@H](N)CN1C(=O)OCC1=CC=CC=C1 MWKAMUJIXBCKIH-WCQYABFASA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229910052593 corundum Inorganic materials 0.000 description 1
- 239000010431 corundum Substances 0.000 description 1
- 238000005388 cross polarization Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 238000000048 melt cooling Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 238000010966 qNMR Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 238000010996 solid-state NMR spectroscopy Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- NNMBHCRWGGSRBE-UHFFFAOYSA-N tert-butyl n-(6-methylpiperidin-3-yl)carbamate Chemical compound CC1CCC(NC(=O)OC(C)(C)C)CN1 NNMBHCRWGGSRBE-UHFFFAOYSA-N 0.000 description 1
- GLNZGGFNQUSLIJ-UHFFFAOYSA-N tert-butyl n-(6-methylpyridin-3-yl)carbamate Chemical compound CC1=CC=C(NC(=O)OC(C)(C)C)C=N1 GLNZGGFNQUSLIJ-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000010977 unit operation Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748628P | 2018-10-22 | 2018-10-22 | |
| US62/748628 | 2018-10-22 | ||
| PCT/IB2019/058940 WO2020084435A1 (en) | 2018-10-22 | 2019-10-21 | Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112888691A CN112888691A (zh) | 2021-06-01 |
| CN112888691B true CN112888691B (zh) | 2023-10-31 |
Family
ID=68343187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980069164.0A Active CN112888691B (zh) | 2018-10-22 | 2019-10-21 | 吡咯并[2,3-d]嘧啶甲苯磺酸盐、其结晶形式以及有关的制备方法和中间体 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12116368B2 (enExample) |
| EP (1) | EP3870584A1 (enExample) |
| JP (1) | JP6944496B2 (enExample) |
| KR (1) | KR102629132B1 (enExample) |
| CN (1) | CN112888691B (enExample) |
| AR (1) | AR116797A1 (enExample) |
| AU (1) | AU2019363840B2 (enExample) |
| BR (1) | BR112021007568A2 (enExample) |
| CA (1) | CA3059000A1 (enExample) |
| IL (1) | IL282446B2 (enExample) |
| MX (1) | MX2021003241A (enExample) |
| SG (1) | SG11202103667QA (enExample) |
| TW (1) | TWI729530B (enExample) |
| WO (1) | WO2020084435A1 (enExample) |
| ZA (1) | ZA202101735B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114761011B (zh) | 2019-08-26 | 2024-06-14 | 肯沃斯公司 | 用作jak1抑制剂的取代的(7h-吡咯并[2,3-d]嘧啶-4-基)氨基化合物 |
| AU2020417043A1 (en) * | 2019-12-31 | 2022-06-09 | Pfizer Inc. | Stable immediate release tablet and capsule formulations of 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one |
| CN113121539A (zh) * | 2019-12-31 | 2021-07-16 | 江苏艾立康医药科技有限公司 | 一种pf06651600的制备方法 |
| CN111620880B (zh) * | 2020-06-15 | 2022-06-10 | 江苏艾立康医药科技有限公司 | Pf-06651600 dl-酒石酸盐，晶型及其制备方法 |
| CN111732591B (zh) * | 2020-06-15 | 2022-06-10 | 江苏艾立康医药科技有限公司 | Pf-06651600 l-酒石酸盐，晶型及其制备方法 |
| CN114835715B (zh) * | 2020-06-15 | 2024-04-05 | 江苏艾立康医药科技有限公司 | Pf-06651600马来酸盐及其制备方法 |
| WO2022012587A1 (zh) * | 2020-07-14 | 2022-01-20 | 苏州晶云药物科技股份有限公司 | 丙烯酮类化合物的丙二酸盐晶型及其制备方法 |
| KR102473645B1 (ko) * | 2020-08-28 | 2022-12-05 | (주)부흥산업사 | (2S,5R)-벤질 5-(t-부톡시카르보닐아미노)-2-메틸피페리딘-1-카르복실레이트의 제조방법 |
| CN112877379B (zh) * | 2021-01-18 | 2023-09-01 | 华南理工大学 | 一种化学酶法合成n-[(3r,6r)-6-甲基哌啶-3-基]氨基甲酸叔丁酯的方法 |
| WO2025144783A1 (en) * | 2023-12-28 | 2025-07-03 | Aclaris Therapeutics, Inc. | Methods of synthesizing substituted pyrrolopyrimidine compounds |
| WO2025146702A1 (en) * | 2024-01-03 | 2025-07-10 | Msn Laboratories Private Limited, R&D Center | Solid state forms of 1-{(2s,5r)-2-methyl-5-[(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino] piperidine-1-yl}prop-2-en-1-one 4-methylbenzene-1-sulfonic acid |
| CN119060059B (zh) * | 2024-08-21 | 2025-10-28 | 武汉九州钰民医药科技有限公司 | 一种甲苯磺酸利特昔替尼的制备工艺 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105859721A (zh) * | 2015-01-22 | 2016-08-17 | 浙江京新药业股份有限公司 | 一种伊布鲁替尼的制备方法 |
| EP3318565A1 (en) * | 2013-12-05 | 2018-05-09 | Pfizer Inc | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS50087B (sr) | 1998-06-19 | 2009-01-22 | Pfizer Products Inc., | Pirolo (2,3-d) pirimidin jedinjenja |
| MA41350A (fr) * | 2015-01-14 | 2017-11-21 | Janssen Pharmaceutica Nv | Synthèse d'un inhibiteur de la tyrosine kinase de bruton |
-
2019
- 2019-10-16 JP JP2019189151A patent/JP6944496B2/ja active Active
- 2019-10-17 CA CA3059000A patent/CA3059000A1/en active Pending
- 2019-10-17 TW TW108137470A patent/TWI729530B/zh active
- 2019-10-21 SG SG11202103667QA patent/SG11202103667QA/en unknown
- 2019-10-21 KR KR1020217015125A patent/KR102629132B1/ko active Active
- 2019-10-21 US US17/286,018 patent/US12116368B2/en active Active
- 2019-10-21 CN CN201980069164.0A patent/CN112888691B/zh active Active
- 2019-10-21 MX MX2021003241A patent/MX2021003241A/es unknown
- 2019-10-21 IL IL282446A patent/IL282446B2/en unknown
- 2019-10-21 BR BR112021007568-2A patent/BR112021007568A2/pt unknown
- 2019-10-21 WO PCT/IB2019/058940 patent/WO2020084435A1/en not_active Ceased
- 2019-10-21 EP EP19794259.2A patent/EP3870584A1/en active Pending
- 2019-10-21 AU AU2019363840A patent/AU2019363840B2/en active Active
- 2019-10-22 AR ARP190103015A patent/AR116797A1/es unknown
-
2021
- 2021-03-15 ZA ZA2021/01735A patent/ZA202101735B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3318565A1 (en) * | 2013-12-05 | 2018-05-09 | Pfizer Inc | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
| CN105859721A (zh) * | 2015-01-22 | 2016-08-17 | 浙江京新药业股份有限公司 | 一种伊布鲁替尼的制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| Atli Thorarensen等.Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1‑((2S,5R)‑5- ((7H‑Pyrrolo[2,3‑d]pyrimidin-4-yl)amino)-2-methylpiperidin-1- yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans.《J. Med. Chem.》.2017,第第60卷卷第1971−1993页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019363840B2 (en) | 2021-12-09 |
| CN112888691A (zh) | 2021-06-01 |
| BR112021007568A2 (pt) | 2021-07-27 |
| KR20210080468A (ko) | 2021-06-30 |
| ZA202101735B (en) | 2022-07-27 |
| MX2021003241A (es) | 2021-05-12 |
| JP6944496B2 (ja) | 2021-10-06 |
| KR102629132B1 (ko) | 2024-01-29 |
| EP3870584A1 (en) | 2021-09-01 |
| IL282446B2 (en) | 2024-06-01 |
| IL282446A (en) | 2021-06-30 |
| TWI729530B (zh) | 2021-06-01 |
| US12116368B2 (en) | 2024-10-15 |
| WO2020084435A1 (en) | 2020-04-30 |
| AR116797A1 (es) | 2021-06-16 |
| CA3059000A1 (en) | 2020-04-22 |
| AU2019363840A1 (en) | 2021-04-01 |
| JP2020066629A (ja) | 2020-04-30 |
| IL282446B1 (en) | 2024-02-01 |
| TW202033525A (zh) | 2020-09-16 |
| SG11202103667QA (en) | 2021-05-28 |
| US20210387989A1 (en) | 2021-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112888691B (zh) | 吡咯并[2,3-d]嘧啶甲苯磺酸盐、其结晶形式以及有关的制备方法和中间体 | |
| US11279705B2 (en) | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt | |
| TWI745831B (zh) | Ｃｄｋ抑制劑之晶形 | |
| KR20230061444A (ko) | Rho-연관 단백질 인산화효소 억제제의 염, 염의 고체 형태, 이의 제조 방법 및 이의 용도 | |
| TW202320757A (zh) | Rho相關蛋白激酶抑制劑或其溶劑合物的固體形式及其製備方法和用途 | |
| TWI820301B (zh) | 結晶型嘧啶基－３，８－二氮雜雙環〔３．２．１〕辛烷基甲酮化合物及其用途 | |
| AU2023263403A1 (en) | Polymorphs of [2-(1H-indol-3-yl)-1H-imidazol-4-yl](3,4,5-trimethoxyphenyl)methanone and its salts | |
| TWI820182B (zh) | 四氫哌喃基胺基－吡咯并嘧啶酮化合物的固體形式 | |
| CA2648369A1 (en) | Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4?l)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide | |
| JP2020073523A (ja) | 置換されたイミダゾピリジニル−アミノピリジン化合物の塩および多型 | |
| RU2849555C2 (ru) | Тозилат пирроло[2,3-d]пиримидина, его кристаллическая форма и способ получения и промежуточные продукты для этой цели | |
| HK40054619A (en) | Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto | |
| HK40054619B (zh) | 吡咯并[2，3-d]嘧啶甲苯磺酸盐、其结晶形式以及有关的制备方法和中间体 | |
| US8729130B2 (en) | Methods of using novel solid forms of tacedinaline | |
| IL308459A (en) | A polymorph of an imidazolidinone compound, its preparation method and use | |
| TWI904227B (zh) | Rho相關蛋白激酶抑制劑的鹽、其固體形式及其製備方法和用途 | |
| CN113840605A (zh) | N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺及其盐的结晶和无定形形式，及其制备方法和治疗用途 | |
| WO2012003413A1 (en) | Novel solid forms of tacedinaline | |
| AU2018201013B2 (en) | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride | |
| JP2025183304A (ja) | Ｒｈｏ関連タンパク質キナーゼ阻害剤の塩、その固体形態、その調製方法およびその使用 | |
| HK40085075B (zh) | Rho相关蛋白激酶抑制剂的盐、其固体形式及其制备方法和用途 | |
| CN119677746A (zh) | Jak抑制剂的固体形式和其制备方法 | |
| HK40083712A (en) | Salt and crystal form of pyrimidine compound, and preparation methods therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40054619 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |